Skip to main content
NCBI home page
Heart logoLink to Heart
. 1998 Jul;80(1):35–39. doi: 10.1136/hrt.80.1.35

Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study

S Chamuleau 1, R J de Winter 1, M Levi 1, R Adams 1, H Buller 1, M Prins 1, K Lie 1, R Peters 1
PMCID: PMC1728751  PMID: 9764056

Abstract

Objective—To investigate the feasibility of fixed dose, weight adjusted subcutaneous low molecular weight heparin (LMWH), with monitoring of anti-Xa levels and assessment of coronary patency rates after three to five days, thereby giving an initial indication of its safety and efficacy.
Design—In 30 patients with acute myocardial infarction, LMWH (nadroparine) was given as a body weight adjusted intravenous bolus with thrombolysis (rt-PA infusion) and in weight adjusted subcutaneous doses at six hours, and every 12 hours thereafter for 72 hours. The target range was defined prospectively as 0.35-0.70 anti-factor Xa activity (aXa) units. The aXa level was measured every six hours. Coronary angiography was performed in all patients within five days after the start of thrombolytic treatment to determine patency (TIMI 2 and 3 flow) of the infarct related artery.
Results—The mean (SEM) aXa level over 72 hours was 0.52 (0.08) U/ml; from 12 hours onwards 88% of all aXa measurements were within the target range. At angiography, a patent infarct related artery was present in 24 of the 30 patients. No major bleeding complications occurred, though minor bleeding complications were observed in two patients.
Conclusions—This small study indicates that LMWH is feasible as an adjunct to thrombolysis in patients with acute myocardial infarction. The aXa levels were within the target range and patency rates at three to five days were around 80%, with no major bleeding complications.

 Keywords: acute myocardial infarction;  thrombolysis;  low molecular weight heparin;  FATIMA study

Full Text

The Full Text of this article is available as a PDF (103.4 KB).

Figure 1  .

Figure 1  

Open in a new tab

The plasma anti-factor Xa activity (aXa; U/ml) measured at 13 time points: just before the start of thrombolytic treatment, six hours after the start, at 12 hours, and every six hours thereafter up to 72 hours after the start of rt-PA infusion. The mean values of the 30 patients per time point are depicted, with their SEM values. The predefined target range was 0.35-0.70 U/ml. From 12 hours onwards 88% of all values were within this range.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman E. M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994 Oct;90(4):1624–1630. doi: 10.1161/01.cir.90.4.1624. [DOI] [PubMed] [Google Scholar]
  2. Arnout J., Simoons M., de Bono D., Rapold H. J., Collen D., Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992 Sep;20(3):513–519. doi: 10.1016/0735-1097(92)90001-4. [DOI] [PubMed] [Google Scholar]
  3. Bleich S. D., Nichols T. C., Schumacher R. R., Cooke D. H., Tate D. A., Teichman S. L. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990 Dec 15;66(20):1412–1417. doi: 10.1016/0002-9149(90)90525-6. [DOI] [PubMed] [Google Scholar]
  4. Chesebro J. H., Knatterud G., Roberts R., Borer J., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Hillis D., Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987 Jul;76(1):142–154. doi: 10.1161/01.cir.76.1.142. [DOI] [PubMed] [Google Scholar]
  5. Collins R., Peto R., Baigent C., Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997 Mar 20;336(12):847–860. doi: 10.1056/NEJM199703203361207. [DOI] [PubMed] [Google Scholar]
  6. Emanuele R. M., Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res. 1987 Dec 1;48(5):591–596. doi: 10.1016/0049-3848(87)90391-4. [DOI] [PubMed] [Google Scholar]
  7. Fuster V. Coronary thrombolysis--a perspective for the practicing physician. N Engl J Med. 1993 Sep 2;329(10):723–725. doi: 10.1056/NEJM199309023291009. [DOI] [PubMed] [Google Scholar]
  8. Hirsh J., Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation. 1994 Mar;89(3):1449–1468. doi: 10.1161/01.cir.89.3.1449. [DOI] [PubMed] [Google Scholar]
  9. Hohnloser S. H., Zabel M., Kasper W., Meinertz T., Just H. Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers. J Am Coll Cardiol. 1991 Jul;18(1):44–49. doi: 10.1016/s0735-1097(10)80215-3. [DOI] [PubMed] [Google Scholar]
  10. Hsia J., Hamilton W. P., Kleiman N., Roberts R., Chaitman B. R., Ross A. M. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med. 1990 Nov 22;323(21):1433–1437. doi: 10.1056/NEJM199011223232101. [DOI] [PubMed] [Google Scholar]
  11. Klein W., Buchwald A., Hillis S. E., Monrad S., Sanz G., Turpie A. G., van der Meer J., Olaisson E., Undeland S., Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) Circulation. 1997 Jul 1;96(1):61–68. doi: 10.1161/01.cir.96.1.61. [DOI] [PubMed] [Google Scholar]
  12. Koopman M. M., Prandoni P., Piovella F., Ockelford P. A., Brandjes D. P., van der Meer J., Gallus A. S., Simonneau G., Chesterman C. H., Prins M. H. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996 Mar 14;334(11):682–687. doi: 10.1056/NEJM199603143341102. [DOI] [PubMed] [Google Scholar]
  13. Kroon C., ten Hove W. R., de Boer A., Kroon J. M., van der Pol J. M., Harthoorn-Lasthuizen E. J., Schoemaker H. C., van der Meer F. J., Cohen A. F. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation. 1992 Nov;86(5):1370–1375. doi: 10.1161/01.cir.86.5.1370. [DOI] [PubMed] [Google Scholar]
  14. Neuhaus K. L., von Essen R., Tebbe U., Jessel A., Heinrichs H., Mäurer W., Döring W., Harmjanz D., Kötter V., Kalhammer E. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Circulation. 1994 Oct;90(4):1638–1642. doi: 10.1161/01.cir.90.4.1638. [DOI] [PubMed] [Google Scholar]
  15. Prandoni P., Lensing A. W., Büller H. R., Carta M., Cogo A., Vigo M., Casara D., Ruol A., ten Cate J. W. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992 Feb 22;339(8791):441–445. doi: 10.1016/0140-6736(92)91054-c. [DOI] [PubMed] [Google Scholar]
  16. Ridker P. M., Hebert P. R., Fuster V., Hennekens C. H. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet. 1993 Jun 19;341(8860):1574–1577. doi: 10.1016/0140-6736(93)90707-n. [DOI] [PubMed] [Google Scholar]
  17. Strandberg L. E., Kahan T., Lundin P., Svensson J., Erhardt L. Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study. Haemostasis. 1996 Sep-Oct;26(5):247–257. doi: 10.1159/000217215. [DOI] [PubMed] [Google Scholar]
  18. Tew C. J., Lane D. A., Thompson E., Ireland H., Curtis J. R. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222. Br J Haematol. 1988 Nov;70(3):335–340. doi: 10.1111/j.1365-2141.1988.tb02491.x. [DOI] [PubMed] [Google Scholar]
  19. de Bono D. P., Simoons M. L., Tijssen J., Arnold A. E., Betriu A., Burgersdijk C., López Bescos L., Mueller E., Pfisterer M., Van de Werf F. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J. 1992 Feb;67(2):122–128. doi: 10.1136/hrt.67.2.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. ten Cate H., Lamping R. J., Henny C. P., Prins A., ten Cate J. W. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem. 1984 Jun;30(6):860–864. [PubMed] [Google Scholar]
  21. ten Cate J. W., Koopman M. M., Prins M. H., Büller H. R. Treatment of venous thromboembolism. Thromb Haemost. 1995 Jul;74(1):197–203. [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES